MARATTO

article · BMC Oral Health

Prevalence and risk factors for oral human papillomavirus and Epstein-Barr virus co-infections among sexually active males and females in Ibadan, Nigeria

Abstract

BACKGROUND: Co-infection of Human papillomavirus (HPV) and Epstein-Barr virus (EBV) is associated with oral and oropharyngeal cancers. This study examined the prevalence and associated risk factors for oral HPV and EBV co-infection among sexually active individuals in Nigeria. METHODS: This was a secondary analysis of oral samples of some selected participants in the Sexual Behaviour and HPV Infection in Nigerians in Ibadan (SHINI) study. Stored oral samples were analysed for detection of EBV DNA using real-time PCR detection and quantification kits. The socio-demographic characteristics, lifestyle and sexual behaviours, and biological characteristics, including the HPV genotype results, were retrieved from the SHINI study data. The association between oral HPV and EBV co-infection and selected participants' characteristics were examined with chi-square or Fisher exact tests. Unadjusted logistic regression and multivariable hierarchical logistic regressions were performed to identify the significant risk factors with HPV and EBV co-infection. Statistical significance was set at p < 0.05. RESULTS: In total, 104 oral samples were analysed. The prevalence of oral HPV and EBV co-infection was 26.9%. Half (50%) of these participants were positive for EBV, and 45.2% were positive for oral HPV only. Nearly all participants with oral HPV and EBV co-infection were females (96.4%). Sex (p = 0.008), anal HPV infection (p < 0.001), genital HPV (p = 0.002), and HIV status (p = 0.004) were significantly associated with the co-infection. The odds of oral HPV and EBV co-infection was lower among males [ aOR = 0.11, 95% CI: 0.00-14.51]. CONCLUSION: There is high prevalence of oral HPV and EBV co-infection in males and females in Nigeria, with HIV status identified as a significant risk factor. Targeted public health measures, such as HPV vaccination programs especially in high-risk groups are recommended to reduce the burden of oral HPV and EBV co-infection.

Research topics

  • Head and Neck Cancer Studies
  • Cervical Cancer and HPV Research
  • Viral-associated cancers and disorders

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s12903-025-06781-x

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.